Cybin (TSE:CYBN) has released an update.
Cybin Inc. is on the brink of starting a major Phase 3 clinical study for its CYB003 drug aimed at treating Major Depressive Disorder, with expectations of releasing 12-month efficacy data from its Phase 2 study by early Q4 2024. Additionally, the company anticipates year-end 2024 or early Q1 2025 to unveil topline efficacy and safety results for CYB004 in treating Generalized Anxiety Disorder, backed by newly appointed experienced leaders in drug development.
For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.
